PHACTR1 Genotype (rs9349379)

Most people learn about their heart attack risk from cholesterol numbers and blood pressure cuffs. Those measurements miss a quieter layer of risk that you were born with and carry for life. The PHACTR1 rs9349379 variant is one of the most studied pieces of that hidden layer, linked to both common atherosclerotic heart disease and rarer artery problems like spontaneous coronary artery dissection.

This is a one-time genetic test. The result tells you which version of a single letter of DNA you inherited at this spot in your genome, and that letter shapes how your arteries handle stress, inflammation, and a hormone called endothelin-1. Your standard lipid panel will not catch this. It is invisible unless you specifically look.

What This Variant Actually Is

PHACTR1 (phosphatase and actin regulator 1) is a gene on chromosome 6 that helps control how blood vessel cells behave, including how they signal inflammation and regulate vessel tone. The rs9349379 variant sits inside this gene but does not change the protein directly. Instead, it acts as a long-distance switch that influences a nearby gene called EDN1, which makes endothelin-1, a powerful hormone that tightens blood vessels. Laboratory studies have shown that the G allele is linked to higher EDN1 activity in vessel-lining and smooth muscle cells.

You inherit one copy from each parent, so your result will be one of three combinations: AA, AG, or GG. Unlike cholesterol, this letter does not move with diet, age, or medication. It is a fixed feature of your biology, set at conception.

The Same Variant Pulls Risk in Opposite Directions

This is the most unusual and important thing to understand. The two letters at this spot do not simply mean "good" or "bad." They steer your risk toward different diseases.

The G letter is linked to higher risk of atherosclerotic heart disease, the buildup of plaque that causes most heart attacks. In a systematic review pooling data across studies, each copy of the G letter raised the odds of coronary artery disease by about 15 percent (odds ratio 1.15, 95% CI 1.13 to 1.17) and raised the odds of calcium buildup in the coronary arteries by about 22 percent (odds ratio 1.22, 95% CI 1.18 to 1.26).

The A letter does the opposite for atherosclerosis, but it raises the risk of non-atherosclerotic artery problems. These are rarer conditions where the artery wall itself becomes fragile or tears. Carrying the A letter has been linked to fibromuscular dysplasia, spontaneous coronary artery dissection, cervical artery dissection, and migraine.

Reconciling the Counterintuitive Finding

It seems contradictory that one letter could protect against heart attacks but raise the risk of artery tears. The framework that makes both findings consistent is that this variant is not a generic "good or bad" marker. It is a phenotype indicator that shifts the personality of your blood vessels. The G version produces patterns that favor plaque-driven disease. The A version produces patterns that favor structural weakness in the artery wall. Different phenotypes carry different risks for different diseases, and your standard labs will not tell you which side of this you are on.

Heart Attack and Coronary Artery Disease

The G letter is one of the most replicated common genetic risk factors for heart attack. Multiple large genome-wide studies in European, Chinese, Mexican, and Lebanese populations have confirmed the link. In large meta-analyses, the per-allele effect is consistently around a 15 percent increase in odds of coronary artery disease per copy of G. Some subgroup analyses, including a Chinese Han study comparing GG to AA under a recessive model, have reported larger effects, but the typical per-allele estimate in pooled data sits near 15 percent. Importantly, the effect acts independently of cholesterol, blood pressure, and blood sugar.

That independence matters. Most carriers will never know they have it because their standard cardiovascular labs look unremarkable. Laboratory work suggests the G letter lowers PHACTR1 activity in immune cells called macrophages, impairing their ability to clean up dying cells inside artery walls. The result, in human studies of plaque tissue, is plaques with more dead tissue and thinner caps, the kind more likely to rupture and cause a heart attack.

In one study of people with familial hypercholesterolemia, PHACTR1 genotype helped predict whether someone developed coronary artery disease even when their cholesterol was already very high, suggesting this site may help refine risk on top of standard lipid measurements.

Spontaneous Coronary Artery Dissection (SCAD)

SCAD is a tear in the inner layer of a coronary artery that can cause a heart attack without any traditional risk factors. It overwhelmingly affects women, often in their 40s and 50s. The A letter is one of the strongest known genetic risk factors. Carrying it raises the odds of SCAD by about 67 percent per copy (odds ratio 1.67, 95% CI 1.50 to 1.86).

If you are a woman with a personal or family history of unexplained heart attack, sudden chest pain in midlife, or migraine, knowing your genotype at this site changes the texture of the conversation with your cardiologist.

Fibromuscular Dysplasia and Cervical Artery Dissection

Fibromuscular dysplasia (FMD) is a non-inflammatory artery disease that produces a characteristic "string of beads" pattern in the kidney or neck arteries. It can cause high blood pressure, stroke, or aneurysm. The A letter raises the odds of FMD by about 39 percent per copy (odds ratio 1.39).

For cervical artery dissection, a tear in a neck artery that is a leading cause of stroke in younger adults, the G letter is protective. People with the G letter have about 25 percent lower odds of cervical artery dissection compared to people with the A letter (odds ratio 0.75, 95% CI 0.69 to 0.82).

Migraine

The A letter has been linked to higher migraine risk, while the G letter is protective. The proposed mechanism is the same endothelin-1 pathway that affects the larger arteries, applied to the smaller vessels in the brain that figure into migraine biology.

Sex Differences in Disease Patterns

One of the most striking patterns at this locus is that the two diseases linked to it have very different sex distributions. Atherosclerotic heart attack predominantly affects men. FMD and SCAD predominantly affect women, who make up roughly 80 to 90 percent of cases. The variant itself is inherited the same way in both sexes, and at least one study in a Chinese Han population found the coronary artery disease effect was actually stronger in women. The sex-skewed prevalence of these diseases reflects hormonal, structural, and other vascular differences that go well beyond this single variant.

Your One-Time Result

This is a once-in-a-lifetime test. Your genotype will not change. There is no need to repeat it under any normal circumstance. The value comes not from retesting this variant but from integrating the result into the decisions you make over the next several decades.

What does need ongoing tracking is the downstream phenotype. If you carry the G letter and are concerned about atherosclerosis, that means regular lipid panels with ApoB, hs-CRP, and Lp(a), plus periodic consideration of a coronary calcium score. If you carry the A letter and have any symptoms or family history pointing toward FMD or SCAD, imaging of the relevant arteries is the appropriate companion test, not a repeat of the genotype.

When Results Can Be Misleading

For a genetic test, the usual confounders that distort blood biomarkers (recent meals, exercise, illness, time of day) do not apply. The result depends on the assay design and a few specific issues to know about:

• Variant panel coverage: the test detects only the specific variants it was designed to detect. A result at rs9349379 does not rule out other rare variants in PHACTR1 or in the nearby EDN1 gene.
• Ancestry differences: the frequency of the A and G letters varies across populations. Most evidence linking this variant to outcomes comes from European-ancestry cohorts, with smaller datasets in Chinese, Mexican, and Lebanese populations. The risk estimates may shift slightly in groups underrepresented in current research.
• Clinical-grade vs direct-to-consumer: a clinical genetic test calls genotype with higher accuracy than a typical consumer ancestry product. If you have seen this variant on a 23andMe-style report, confirming it with a clinical-grade assay is reasonable before acting on it.
• Carrying a risk letter does not guarantee disease: most people with the higher-risk letter never develop heart attack, SCAD, or FMD. The variant nudges your odds, it does not seal them.
• Single-variant testing has limits: professional society guidelines do not currently recommend clinical decisions based on a single common variant like this one. The result is most useful as one input alongside standard risk factors and, where available, a broader polygenic risk score.

Decision Pathway for Your Result

What you do with your result depends on which letter you carry and what else is going on in your life. The variant alone does not justify a procedure, a medication, or a referral, but it can inform how thoroughly you and your clinician work through the rest of your cardiovascular picture. Current professional society statements note that clinical action based on a single common variant is not yet guideline-endorsed, so any next steps should be discussed with your physician in the context of your overall risk.

If you carry one or two copies of G, a reasonable conversation with your clinician is whether to lean more heavily on tools like ApoB, Lp(a), and a coronary calcium score, especially if your other risk markers are borderline. The variant on its own is not a directive for treatment, but it can support earlier consideration of these measurements as part of a broader prevention plan.

If you carry one or two copies of A, especially if you are a woman or have a family history of unexplained heart attack, sudden chest pain in midlife, severe migraine, or stroke, the practical move is to mention it to your cardiologist or primary care doctor. If you ever experience chest pain or stroke symptoms, the SCAD and dissection diagnoses should be on the radar from the start. For people with imaging findings or family history suggesting FMD, a referral to a vascular specialist is reasonable.

For anyone with a strong family history of unexplained vascular disease, sudden cardiac events in young relatives, or connective tissue disease, a one-time genetic counseling consultation can help interpret this result alongside other findings and decide whether broader genetic testing is warranted.

How This Differs from Standard Cardiovascular Genetic Testing

Most clinical cardiovascular gene panels look for rare, high-impact mutations that cause inherited disease in a small number of families. This variant is the opposite: a common variant carried by a large share of the population that produces a modest but real shift in risk. Standard panels are unlikely to include it. Whole-genome and whole-exome sequencing reports may flag it as a secondary finding, but most clinical reports do not report common-variant risk markers like this one.